Skip to main content
. 2015 Nov 10;5:16407. doi: 10.1038/srep16407

Figure 5. Antibacterial and anti-inflammatory activities of simvastatin in a mouse model of MRSA skin infection.

Figure 5

(a) Efficacy of treatment of MRSA skin lesions with simvastatin (1 and 3%), mupirocin (2%) and petroleum jelly (negative control) once daily for four days. Percent bacterial reduction was calculated and shown in the figure. Statistical analysis was performed via the two-tailed Student t test. P values of (**P ≤ 0.01) are considered as significant. Detailed P values are listed: Control vs mupirocin (2%), <0.0001; Control vs simvastatin (1%), <0.0001; Control vs simvastatin (3%), <0.0001. (b) Effect of simvastatin on cytokines production in supernatants from skin homogenates of MRSA skin lesions. Percent reduction in inflammatory cytokines was calculated. Statistical analysis was performed via the two-tailed Student t test. P values of (**P ≤ 0.01) are considered as significant. Detailed P values are listed: IL-6: Control vs simvastatin (1%), 0.0013; Control vs simvastatin (3%), 0.0041. TNF-α: Control vs simvastatin (1%), 0.0030; Control vs simvastatin (3%), 0.0166. IL-1β: Control vs simvastatin (1%), 0.0205; Control vs simvastatin (3%), 0.0037.